OBJECTIVES: Controlled trials have found therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) infusion therapy to be equally efficacious in treating Guillain-Barré syndrome (GBS). Due to increases in the price of IVIg compared to human serum albumin (HSA), used as a replacement fluid in TPE, direct hospital-level expenditures for TPE and IVIg for meaningful cost-differences between these treatments were exemined for Turkey. METHODS: Cost were calculated with Hacettepe University Hospital procedures for one cycle IVIg and TPE. One cycle were defined for IVIg and TPE as 5 days and 5 series, respectively. A model was developed which allows hospitals to input cost and reimbursement amounts for both IVIg and TPE with HSA that results in real-time valuations of these interventions. Reimbursement amounts were obtained from publicly available Social Security Institution (SGK) data resources to determine payment rates for TPE and IVIg. Only direct cost and payer perspective were used for the calculation.  RESULTS: The direct cost of IVIg infusion sessions totaling 140,0 grams for 5 days was 18,841 TL  compared to a series of five TPE procedures, which had direct costs of 6,529 TL CONCLUSIONS: In GBS patients, direct costs of IVIg therapy are more than twice that of TPE. Given equivalent efficacy and similar severity and frequencies of adverse events, TPE appears to be a less expensive first-line therapy option for treatment of patients with GBS for Turkey.